The Zhitong Finance App learned that Nomura released a research report saying that Sinopharm Holdings' (01099) sales forecast for fiscal year 2023 remained roughly unchanged, while raising the profit forecast by 2% to reflect the improvement in the financing environment since the next quarter and maintain the “buy” rating, but the target price was lowered from HK$36.88 to HK$36.28.

The bank estimates that Sinopharm's sales will increase by 8.1% in the next quarter, while net profit will increase by 5.9% to 2.4 billion yuan, and gross margin may remain at around 8.7%. By business, it is estimated that Sinopharm's pharmaceutical distribution, medical device distribution, and pharmacy retail sales will increase by 10%/15%/15%, respectively, to 2070/610/17 billion yuan in the first half of the year.